18F-fluorothymidine PET for predicting survival in patients with resectable pancreatic cancer

PURPOSEThe aim of this study was to correlate preoperative 3'-deoxy-3'-[18F] fluorothymidine (FLT) uptake with the clinical outcome and survival in these patients after surgery. MATERIALS AND METHODSWe performed a prospective analysis in 27 patients with adenocarcinoma of the pancreas (15...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2018-02, Vol.9 (11), p.10128-10134
Main Authors: Wieder, Hinrich, Beer, Ambros J., Siveke, Jens, Schuster, Tibor, Buck, Andreas K., Herrmann, Ken, Stollfuss, Jens C.
Format: Article
Language:English
Subjects:
Clinical Research Paper
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:PURPOSEThe aim of this study was to correlate preoperative 3'-deoxy-3'-[18F] fluorothymidine (FLT) uptake with the clinical outcome and survival in these patients after surgery. MATERIALS AND METHODSWe performed a prospective analysis in 27 patients with adenocarcinoma of the pancreas (15 males, 12 females, mean age: 62 ± 13 years, range: 34 - 86 years). FLT PET (45 min p.i., 300 MBq FLT; ECAT HR+) images were acquired according to standard protocols. FLT uptake was quantified using standardised uptake values (SUV). Mean follow-up was 35 months (range 24-49). FLT uptake was correlated with survival using Martingale residual analysis. RESULTSTwenty-two patients died during follow-up. Mean overall survival was 18.8 months (SD: 12.7 months, 95% CI: 7.7, 26.5). FLT PET showed a mean SUV of 2.5 (range: 1.1 - 6.5). Martingale residual analysis revealed significant correlation between survival and FLT uptake (p = 0.045). The corresponding estimated hazard ratio per one-point increment of SUVmean was 1.298 (95% CI: 1.001, 1.685; p < 0.05). CONCLUSIONSFLT PET allows risk stratification for death in patients with resectable pancreatic cancer prior to surgery.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.24176